News

Thursday, 08 May 2019

Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein


Press release by Savara Pharmaceuticals

Read more


Wednesday, 01 May 2019

Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019


Sunovion Pharmaceuticals Inc. will present data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.

Read more


Tuesday, 26 March 2019

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.


Breath Therapeutics’ lead drug candidate, L-CsA-i, is a proprietary liposomal formulation of cyclosporine A for inhalation administered via a drug-specific investigational eFlow® Technology nebuliser.

Read more


Tuesday, 02 October 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).


ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

Read more


Thursday, 07 December 2017

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)


LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!
eFlow-partneringpari.com